Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients

Exclusion Criteria

• •Previous or ongoing treatment for any PCSK9i
• •Allergy to PCSK9i, statins, or any of the drug ingredients used during the trial
• •History of hemorrhagic cerebrovascular disease
• •History of old myocardial infarction/chronic heart failure
• •History of PCI or coronary artery bypass grafting (CABG) or preparation for CABG
• •Above Killip level II
• •Prolonged cardiopulmonary resuscitation (\>20min)
• •Definite mechanical complications (including perforation of the interventricular septum, or rupture of the papillary tendon bundle or the left ventricular free wall)
• •malignant arrhythmia
• •Severe uncontrolled infection, bleeding disorder, end-stage renal disease, severe liver disease, endocrine dysfunction, or the expected less than 1 year survival of malignant tumors
• •Pregnant or lactating women
• •Participate in other clinical trials